Article Text

Download PDFPDF
Candidate rheumatologic treatments for COVID-19. Response to: ‘COVID-19 infection in a patient with FMF: does colchicine have a protective effect?’ by Kobak
  1. Sara Monti,
  2. Carlomaurizio Montecucco
  1. Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia 27100, Italy
  1. Correspondence to Dr Sara Monti, Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia 27100, Italy; sara.saramonti{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We appreciate the comment from Dr Kobak1 to our previously published report on the clinical course and outcome of COVID-19 in a cohort of patients treated with biologic and targeted synthetic disease modifying antirheumatic drugs.2 The author described the case of a patient with familial Mediterranean fever treated with colchicine who experienced a mild course of …

View Full Text


  • Handling editor Josef S Smolen

  • Contributors SM and CM contributed equally to the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting or dissemination plans of this research.

  • Patient consent for publication Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles